Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

10.34USD
2:29am IST
Change (% chg)

$0.75 (+7.82%)
Prev Close
$9.59
Open
$10.20
Day's High
$10.55
Day's Low
$9.66
Volume
700,513
Avg. Vol
315,376
52-wk High
$15.01
52-wk Low
$4.10

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $644.09
Shares Outstanding(Mil.): 72.70
Dividend: --
Yield (%): --

Financials

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

12 Jan 2018

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

Jan 11 A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

12 Jan 2018

BRIEF-Insys' Treatment For Prader-Willi Syndrome Gets ‘Fast Track’ Designation

* FDA GRANTS INSYS THERAPEUTICS ‘FAST TRACK’ DESIGNATION FOR CANNABIDIOL (CBD) ORAL SOLUTION AS INVESTIGATIONAL TREATMENT FOR PRADER-WILLI SYNDROME

26 Dec 2017

North Carolina accuses drugmaker Insys of scheme to push opioid

BOSTON North Carolina sued Insys Therapeutics Inc on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

22 Dec 2017

REFILE-UPDATE 1-North Carolina accuses drugmaker Insys of scheme to push opioid

BOSTON, Dec 21 North Carolina sued Insys Therapeutics Inc on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

21 Dec 2017

North Carolina sues drugmaker Insys over role in opioid epidemic

Dec 21 North Carolina on Thursday sued Insys Therapeutics Inc over its role in the opioid epidemic, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys in a quest to make more money.

21 Dec 2017

UPDATE 1-New Mexico adds Insys, Mallinckrodt to opioid epidemic lawsuit

Dec 20 New Mexico on Wednesday added claims against drugmakers Insys Therapeutics Inc and Mallinckrodt Plc in a lawsuit accusing various opioid manufacturers and distributors of helping fuel a drug addiction epidemic in the state.

21 Dec 2017

New Mexico adds Insys, Mallinckrodt to opioid epidemic lawsuit

Dec 20 New Mexico on Wednesday added claims against drugmakers Insys Therapeutics Inc and Mallinckrodt Plc in a lawsuit accusing various opioid manufacturers and distributors of helping fuel a drug addiction epidemic in the state.

21 Dec 2017

BRIEF-Insys Therapeutics Inc - ‍Study Is Expected To Be Completed In Late 2018 For Of Cbd Oral Solution-A​

* INSYS THERAPEUTICS INITIATES PHASE 2 CLINICAL TRIAL OF CANNABIDIOL (CBD) ORAL SOLUTION FOR TREATMENT OF REFRACTORY CHILDHOOD ABSENCE EPILEPSY IN PEDIATRIC PATIENTS

19 Dec 2017

BRIEF-Insys Therapeutics' NDA For Buprenorphine Sublingual Spray Accepted By FDA

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) FOR BUPRENORPHINE SUBLINGUAL SPRAY FROM INSYS THERAPEUTICS

06 Dec 2017

Earnings vs. Estimates